ARID1A and cancer: Shen et al. discovered that ARID1A deficiency impairs checkpoint activation and DNA double-strand breaks (DSB) repair, rendering cancer cells susceptible to DSB-inducing treatments such as ionizing radiation (IR) and PARP inhibitors [7].